JO
MDGL icon

John Overdeck’s Madrigal Pharmaceuticals MDGL Stock Holding History

John Overdeck’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
+3,200
New +$1.64M ﹤0.01% 3140

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's MDGL Position: Q2 2026 in Review

John Overdeck opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 566 shares worth $304K. The stake represents ﹤0.01% of the portfolio and ranks #4519 among its holdings. This is a return to the name: John Overdeck previously reported a position in MDGL as recently as Q1 2023.

John Overdeck first reported a position in MDGL in Q4 2013 and has held it in 15 quarters since. The position peaked at $21.1M in Q1 2021. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • John Overdeck held 566 shares of Madrigal Pharmaceuticals worth $304K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new John Overdeck position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4519 holding.
  • John Overdeck first reported a position in Madrigal Pharmaceuticals in Q4 2013 and has held it in 15 quarters since.
  • John Overdeck's Madrigal Pharmaceuticals position peaked at $21.1M in Q1 2021.
  • 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.